Business Wire

RAPYD

22.9.2022 09:57:36 CEST | Business Wire | Press release

Share
REPORT: Nearly 70% of Europeans Prefer Direct Bank Transfers As Top Preferred Method to Get Paid, According to Rapyd

Nearly seven out of 10 (67%) Europeans demand direct bank transfers as their most preferred method to be paid, indicating the growing need for businesses to provide fast and secure payments in consumers’ preferred payout methods.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220922005160/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Source: Rapyd’s 2022 European eCommerce and Payment Methods report (Graphic: Business Wire)

That’s according to a new report released by Rapyd, the leading fintech-as-a-service partner, after conducting research to understand consumer choices, considerations and preferences in nine European countries; including data on how consumers prefer to pay and receive payments.

Rapyd’s European State of Disbursements report finds that access to, and interest in, financial technology apps is very high among consumers in the nine European markets surveyed. Europeans are embracing financial services apps for everything from banking, everyday spending and managing their investments. The findings show that 74% of European consumers use a mobile banking app, 50% use an eWallet app, 50% use a credit or debit card app, approximately one in six (16%) use an investment fund app and approximately one in eight (12%) use a personal financial management app.

Rapyd’s European eCommerce and Payment Methods report also indicates that Europeans increasingly rely on phones for payments, financial management and eCommerce. Over half (52%) of Europeans report purchasing clothes online via mobile over the past three months, compared to 46% via laptop. Furthermore, the overwhelming majority of Europeans who purchased takeaway over the last 3 months did so via mobile (70%) compared to laptop (28%).

Rapyd’s State of Disbursements report also noted that Europeans are early adopters of fintech, prioritizing data security and lower costs when receiving payments. Only 16% are hesitant or lagging in the adoption of fintech. The data shows that 82% rank keeping their personal information secure as the most important feature for payouts, and over 70% of respondents do not want to pay any transaction fees.

The report further analyzes and compares each market’s attitudes towards fintech adoption. Interestingly, Spain had the highest number of early adopters or consumers more likely to be open to new fintech solutions (27%), followed by Iceland (22%) and Germany (20%). On the other hand, Denmark (54%), France (47%) and the UK (44%) had the highest number of consumers who identified as the ‘late majority.’ The analysis notes that these consumers are less likely to explore new financial technology, instead preferring to use the same platforms as family and friends.

Over half of global online transfers are currently made with local or alternative payment methods. This, coupled with the rapid growth of marketplaces and gig economy models, is driving the need for new payout technology in Europe, notes the report.

Rapyd also notes that with the roll-out of the Single Euro Payments Area (SEPA) continuing and the Nordics’ P27 payments initiative unfolding, real-time payments in Europe are here to stay, emphasizing the need to keep abreast of country-specific regulations. As such, the company is calling on businesses to ensure they have the infrastructure in place to guarantee reliable mass payouts driven by local preferences.

Commenting on the findings, Arik Shtilman, CEO of Rapyd, said:

“The companies that solve the technological challenges of disbursing funds in Europe will surge ahead of their competition. It’s critical that businesses responsible for online financial transactions have partners that can support them in delivering reliable payout and payment solutions, can keep on top of local regulations and can stay on top of consumer preferences. The businesses that invest in dynamic tech solutions to guarantee reliable mass payouts will no doubt enjoy stability and growth through better engagement, loyalty and beneficiary preference.

“Furthermore, given the growth of marketplaces and gig-economy platforms, working with partners that understand the evolving fintech space is key. Disbursing funds to a seller or worker is typically tied to individual sales on different platforms. This can be incredibly complex, as in many cases, the buyer, seller and platform provider are all in different locations. We recommend that businesses ensure local preferences are driving their payout strategy, with a particular focus on speed, security and choice, as these factors help drive greater use and adoption and build loyalty and trust.”

Rapyd’s 2022 European eCommerce and Payment Methods report and 2022 European State of Disbursements report are available here.

Notes to Editors:

Survey Methodology

Rapyd surveyed 4,286 adults (18+) in Denmark, France, Germany, Iceland, Italy, Netherlands, Sweden, Spain and the United Kingdom online in March and April 2022. All respondents made an online purchase in the previous month and were nationally representative across age and income scale.

About Rapyd

Rapyd lets you build bold. Liberate global commerce with all the tools your business needs to create payment, payout and fintech experiences everywhere. From Fortune 500s to ambitious business and technology upstarts, our payments network and powerful fintech platform make it easy to pay suppliers and get paid by customers—locally or internationally.

With offices worldwide, including Tel Aviv, Dubai, London, Iceland, San Francisco, Miami and Singapore, we know what it takes to make cross-border commerce as easy as being next door. Rapyd simplifies payments so you can focus on building your business.

Get the tools to grow globally at www.rapyd.net. Follow: Blog, Insta, LinkedIn, Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220922005160/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye